Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.
TD-1792 is a new multivalent glycopeptide-cephalosporin antibiotic with potent activity against Gram-positive bacteria. The in vitro activity of TD-1792 was tested against 527 Staphylococcus aureus isolates, including multidrug-resistant isolates. TD-1792 was highly active against methicillin-susceptible S. aureus (MIC(90), 0.015 μg/ml), methicillin-resistant S. aureus, and heterogeneous vancomycin-intermediate S. aureus (MIC(90), 0.03 μg/ml). Time-kill studies demonstrated the potent bactericidal activity of TD-1792 at concentrations of ≤ 0.12 μg/ml. A postantibiotic effect of >2 h was observed after exposure to TD-1792.
Theravance, Inc, South San Francisco, California, USA.
Johanne
J
Blais
Stacey R
SR
Lewis
Kevin M
KM
Krause
Bret M
BM
Benton
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D002511:Cephalosporins / Q000737:chemistry / Q000494:pharmacology*; D015169:Colony Count, Microbial; D024901:Drug Resistance, Multiple, Bacterial; D006020:Glycopeptides / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008712:Methicillin / Q000494:pharmacology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D006020:Glycopeptides; D008712:Methicillin; D014640:Vancomycin; C539430:cefilavancin